Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257376 | 0.94 | TP53 (0.47) | TP53THRBLMNAENPP2MEN1 | |
| SCHEMBL16257239 | 0.93 | TP53 (0.48) | TP53THRBLMNAMEN1KMT2A | |
| SCHEMBL16237446 | 0.92 | TP53 (0.45) | TP53THRBLMNAENPP2MEN1 | |
| SCHEMBL16237205 | 0.91 | TP53 (0.46) | TP53THRBLMNAMEN1KMT2A | |
| SCHEMBL16238009 | 0.87 | TP53 (0.45) | TP53THRBLMNAMEN1KMT2A | |
| SCHEMBL16257238 | 0.87 | THRB (0.49) | TP53THRBLMNAMEN1KMT2A | |
| SCHEMBL16257326 | 0.86 | TP53 (0.46) | TP53THRBLMNAENPP2POLB | |
| SCHEMBL16237196 | 0.86 | THRB (0.50) | TP53THRBLMNAPOLB | |
| SCHEMBL17700831 | 0.85 | HTR2B (0.46) | TP53THRBLMNAMEN1KMT2A | |
| SCHEMBL16257339 | 0.84 | TP53 (0.49) | TP53THRBLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | TP53 102/4885THRB 3197/4885LMNA 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.